A E Foster

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi T cells enhance gold nanoparticle delivery to tumors in vivo
    Laura C Kennedy
    Department of Bioengineering, Rice University, Houston, TX 77005, USA
    Nanoscale Res Lett 6:283. 2011
  2. ncbi Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine
    A E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Leukemia 24:563-72. 2010
  3. ncbi Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression
    Aaron E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, 77030 USA
    Mol Cancer 8:106. 2009
  4. ncbi In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye
    Aaron E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, 1102 Bates Street, Houston, Texas 77030, USA
    Appl Opt 47:5944-52. 2008
  5. ncbi A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy
    C Hirschmann-Jax
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas, USA
    Cell Cycle 4:203-5. 2005
  6. ncbi A distinct "side population" of cells with high drug efflux capacity in human tumor cells
    C Hirschmann-Jax
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, and DeBakey Department of Surgery, One Baylor Plaza, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 101:14228-33. 2004
  7. ncbi Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma
    Jessica A Shafer
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:870-80. 2010
  8. ncbi Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 110:2620-30. 2007
  9. ncbi Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes
    Anjum S Kaka
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    J Immunother 32:726-36. 2009
  10. ncbi IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity
    Meghan E Turnis
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    J Immunol 185:4223-32. 2010

Collaborators

Detail Information

Publications17

  1. ncbi T cells enhance gold nanoparticle delivery to tumors in vivo
    Laura C Kennedy
    Department of Bioengineering, Rice University, Houston, TX 77005, USA
    Nanoscale Res Lett 6:283. 2011
    ..Thus, the use of T cell chaperones for AuNP delivery could enhance the efficacy of nanoparticle-based therapies and imaging applications by increasing AuNP tumor accumulation...
  2. ncbi Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine
    A E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Leukemia 24:563-72. 2010
    ..Hence, malignant B cells with a primary drug-resistant phenotype can be targeted by T- cell-mediated effector activity after immunization of human subjects...
  3. ncbi Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression
    Aaron E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, 77030 USA
    Mol Cancer 8:106. 2009
    ..This outcome supports the presence of a rare population of precursor/progenitor cells in human malignancies, and suggests benefit from their removal...
  4. ncbi In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye
    Aaron E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, 1102 Bates Street, Houston, Texas 77030, USA
    Appl Opt 47:5944-52. 2008
    ..Together, these data suggest that IRDye800CW may be used to study the trafficking of T cells in a small animal model and may have potential as a short-term reporter molecule for human immunotherapy studies...
  5. ncbi A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy
    C Hirschmann-Jax
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas, USA
    Cell Cycle 4:203-5. 2005
    ..Identification of a tumor progenitor population with intrinsic mechanisms for cytostatic drug resistance might also provide clues for improved therapeutic intervention...
  6. ncbi A distinct "side population" of cells with high drug efflux capacity in human tumor cells
    C Hirschmann-Jax
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, and DeBakey Department of Surgery, One Baylor Plaza, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 101:14228-33. 2004
    ....
  7. ncbi Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma
    Jessica A Shafer
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:870-80. 2010
    ..This study suggests that chemoresistant HL SP cells can be targeted by the immune system, providing a rationale for combined chemotherapy and immunotherapy for the treatment of HL...
  8. ncbi Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
    Barbara Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
    Blood 110:2620-30. 2007
    ..EBV-CTLs expressing both a native and a chimeric antigen receptor may therefore have added value for treatment of HD...
  9. ncbi Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes
    Anjum S Kaka
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
    J Immunother 32:726-36. 2009
    ....
  10. ncbi IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity
    Meghan E Turnis
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    J Immunol 185:4223-32. 2010
    ..f10 tumor-bearing mice, without discernible induction of autoimmune disease. Thus, manipulation of IRAK-M levels can increase the potency of DC vaccines by enhancing their Ag-presenting function, migration, and longevity...
  11. ncbi Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7
    Juan F Vera
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
    Mol Ther 17:880-8. 2009
    ..This approach may allow selective expansion of CTLs without the unwanted effects associated with IL-2...
  12. ncbi Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
    Concetta Quintarelli
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 110:2793-802. 2007
    ..We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach...
  13. ncbi Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12
    Aaron E Foster
    Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, 6621 Fannin Street, Houston, TX 77030, USA
    J Immunother 30:506-16. 2007
    ..Thus, T cells provide a platform for the generation of autologous APC that can be customized to express both antigens and therapeutic molecules for the induction of antigen-specific T cell immunity...
  14. ncbi Improving T cell therapy for cancer
    Ann M Leen
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Annu Rev Immunol 25:243-65. 2007
    ..In this review, we discuss current, promising strategies to improve adoptive T cell therapy for the treatment of cancer...
  15. ncbi Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor
    Aaron E Foster
    Center for Cell and Gene Therapy, The Methodist Hospital and Texas Children s Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
    J Immunother 31:500-5. 2008
    ..TGF-beta-resistant CTL had a functional advantage over unmodified CTL in the presence of TGF-beta-secreting EBV-positive lymphoma, and had enhanced antitumor activity, supporting the potential value of this countermeasure...
  16. ncbi Improving T cell therapy for cancer
    Aaron E Foster
    Center for Cell and Gene Therapy, The Methodist Hospital and Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
    Expert Opin Biol Ther 6:215-29. 2006
    ....
  17. ncbi T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
    Antonio Di Stasi
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
    Blood 113:6392-402. 2009
    ..This approach may be of value in patients affected by HL...